Active Recombinant Human KDR, Fc Chimera

• Cat.No.: KDR-236H
• Product Overview: Recombinant Human KDR (Accession # AAC16450) was produced in Mouse myeloma cell line, NS0-derived.

Specification

• Source: Mammalian cells
• Species: Human
• Tag: Fc Chimera
• Predicted N Terminal: Ala20
• Form: Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein.
• Bio-activity: Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells.The ED50 for this effect is typically 10-40 ng/mL in the presence of 5 ng/mL rhVEGF165.
• Molecular Mass: Recombinant Human KDR, Fc Chimera has a calculated MW of 110 kDa (monomer). In SDS-PAGE migrates as 160-170 kDa, reducing conditions.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Storage: Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).
• Reconstitution: Reconstitute at 100 µg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.

Gene Information

• Gene Name: KDR kinase insert domain receptor (a type III receptor tyrosine kinase) [ Homo sapiens ]
• Official Symbol: KDR
• Synonyms: KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); vascular endothelial growth factor receptor 2; CD309; FLK1; VEGFR; VEGFR2; soluble VEGFR2; fetal liver kinase 1; fetal liver kinase-1; protein-tyrosine kinase receptor Flk-1; tyrosine kinase growth factor receptor
• Gene ID: 3791
• mRNA Refseq: NM_002253
• Protein Refseq: NP_002244
• MIM: 191306
• UniProt ID: P35968
• Chromosome Location: 4q11-q12